EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Colchicine Use and Major Adverse Cardiovascular Events in Male Patients with Gout and Established Coronary Artery Disease: A Veterans Affairs Nested Retrospective Cohort Study

Gary H Ho iD, Michael Toprover iD, Daria B Crittenden, Binita Shah, Michael H Pillinger

Gout, Urate, and Crystal Deposition Disease · 15.03.2023 · 1 (1) · 11-24

DOI: 10.3390/gucdd1010003 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Gout, Urate, and Crystal Deposition Disease, online erschienen am 15.03.2023. Verfasst von Gary H Ho und 4 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Section, Department of Medicine, Margaret Cochran Corbin Campus of the New York Harbor Health Care System, United States Department of V…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite colchicine’s proven efficacy in the non-gout population, the effects of colchicine on the risk of major adverse cardiovascular events (MACE) among high-risk patients with gout remain to be determined. The purpose of this study is to evaluate the association between colchicine use and MACE in gout patients with preexisting coronary artery disease (CAD).

Methods

This retrospective cohort study followed patients with gout and established CAD within the VA New York Harbor Healthcare System who did or did not use colchicine regularly (>30 continuous days prescription with at least 1 refill). The primary outcome was first MACE, defined as a composite of non-fatal myocardial infarction, coronary artery bypass graft, non-fatal stroke, and all-cause mortality. Part I of the primary analysis compared MACE between colchicine users and nonusers. Part II of the study compared MACE within the colchicine-use group, divided into quartiles based on consistency of colchicine use (i.e., percentage of time on colchicine).

Results

Among 1638 patients with gout, 355 had established CAD (239 colchicine users and 116 nonusers). In this cohort, the odds of MACE were similar between any colchicine use compared to nonuse (OR 1.14; 95% CI (0.59–2.20)); however, colchicine users overall had a higher baseline cardiovascular risk profile than nonusers, suggesting that colchicine may have served to equilibrate risk between the two groups. Moreover, patients in the highest continuous colchicine-use quartile (>70% of observation period on colchicine) demonstrated lower odds of MACE compared to those in the lowest three quartiles (OR 0.35; 95% CI (0.13–0.93)), with no difference in baseline risk. Additionally, colchicine users had a numerically lower rate of MACE during periods of active use compared with periods of lapse. Kaplan–Meier analysis revealed a difference in cumulative MACE over time, favoring the subgroup with the most consistent colchicine use (plog-rank = 0.01).

Conclusions

Despite higher CV risk, gout patients with CAD receiving colchicine had no higher rates of MACE than those not receiving colchicine. Among all patients with gout and CAD treated with colchicine, those with the most consistent colchicine use had lower odds of MACE, and event rates were lower during active use. Colchicine protection against cardiovascular events may require maintenance of colchicine bloodstream levels.

Schlagwörter

Stichwörter der Autor:innen

cardiovascular riskcolchicinegoutmajor adverse cardiovascular events

Autor:innen und Institutionen

  • Rheumatology Section, Department of Medicine, Margaret Cochran Corbin Campus of the New York Harbor Health Care System, United States Department of Veterans Affairs, New York, NY 10010, USA.
  • Division of Rheumatology, Department of Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA.
  • Cardiology Section, Department of Medicine, Margaret Cochran Corbin Campus of the New York Harbor Health Care System, United States Department of Veterans Affairs, New York, NY 10010, USA.
  • Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA.

ORCID-Profile: Gary H Ho, Michael Toprover

Förderung

  • NCATS NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Ho, G. H., Toprover, M., Crittenden, D. B., Shah, B., & Pillinger, M. H. (2023). Colchicine Use and Major Adverse Cardiovascular Events in Male Patients with Gout and Established Coronary Artery Disease: A Veterans Affairs Nested Retrospective Cohort Study. Gout, Urate, and Crystal Deposition Disease, 1(1), 11-24. https://doi.org/10.3390/gucdd1010003

Vancouver

Ho GH, Toprover M, Crittenden DB, Shah B, Pillinger MH. Colchicine Use and Major Adverse Cardiovascular Events in Male Patients with Gout and Established Coronary Artery Disease: A Veterans Affairs Nested Retrospective Cohort Study. Gout, Urate, and Crystal Deposition Disease. 2023;1(1):11-24. doi:10.3390/gucdd1010003

BibTeX
@article{Ho2023,
  author = {Ho, Gary H and Toprover, Michael and Crittenden, Daria B and Shah, Binita and Pillinger, Michael H},
  title = {Colchicine Use and Major Adverse Cardiovascular Events in Male Patients with Gout and Established Coronary Artery Disease: A Veterans Affairs Nested Retrospective Cohort Study},
  journal = {Gout, Urate, and Crystal Deposition Disease},
  year = {2023},
  volume = {1},
  number = {1},
  pages = {11--24},
  doi = {10.3390/gucdd1010003}
}
Kostenlos starten →